ARWR

Arrowhead Pharmaceuticals, Inc.

$74.11 -2.29 (-3.00%) At close · Jul 13

Market Cap

$10.13B

140,857,021

Up next

Next earnings call

Aug 4, 2026 Est · unconfirmed · in 3 wks

FQ4-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.5 · calm Equity put/call 0.62

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +20%

above

Price vs 50-day avg −4%

below

RSI (14) 40

neutral

MACD trend Negative

52-week position 81%

mid-range

Momentum

relative strength

Very Strong

1-month return 0%

trailing

6-month return +16%

trailing

YTD return +12%

this year

Relative strength +8%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $78 › 200d $62 — 50d above 200d

Institutional flow Accumulating

25 of 442 funds reported for Jun 30 · net +190.4K sh shares · +8 new

Insider flow Distributing

Net -$1.9M over 90 days · 100% sells

Short interest Falling

5.99% of float · ▼ -28.2% MoM · 2.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

442 holders — near 3-yr high, broad support

Squeeze score 52

elevated · 0–100

Fundamentals

Strong

Revenue growth −49%

Y/Y

EPS growth +100%

Y/Y

Free cash flow $156.9M

Balance sheet $184.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 66%

annualized · 1-yr

Max drawdown −25%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+20% Bullish

Price vs 50-day avg

−4% Neutral

RSI (14)

40 Neutral

MACD trend

Negative Bearish

52-week position

81% Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $78 › 200d $62 — 50d above 200d

Institutional flow Accumulating

25 of 442 funds reported for Jun 30 · net +190.4K sh shares · +8 new

Insider flow Distributing

Net -$1.9M over 90 days · 100% sells

Short interest Falling

5.99% of float · ▼ -28.2% MoM · 2.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

442 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $14 Now $74 · 81% 52-wk high $88

vs 200-day avg +20% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
New written prescriptions per week	30	currently averaging	—
Patients who have received at least one pre-filled syringe shipment	180	since launch through May 7, 2026	—
Total prescriptions received and in process to date	400	since launch through May 7, 2026	—
prescriptions from patients naive to the APOC3 class	85%	fiscal second quarter ending March 31, 2026 call	—
REDEMPLO U.S. wholesale acquisition cost (WAC)	$45,000	fiscal second quarter ending March 31, 2026 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARWR Arrowhead Pharmaceuticals, Inc. this stock	$10.13B	+11.6%	-48.6%	—	6.0%
ONC BeOne Medicines Ltd.	$439.30B	+0.0%	+22179.2%	894.0	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$121.89B	+5.9%	+46.2%	28.5	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$69.52B	-14.0%	+20.8%	16.2	3.3%
ARGX Argenx SE	$53.71B	+4.2%	—	—	2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

449

% held: 82.6%
Reported: 25 of 442
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

443

View

Short & Settlement

Short Interest Falling

Shares short

8.4M

Days to cover: 2.2d
Change: -3.3M sh

View

Short Volume

Short vol %

66%

As of: Jul 14, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $521
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

47.2%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.9M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$829.4M

Net income (FY): $-1.6M
EPS diluted: $-0.01

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 16, 2026
This year: 12

View

Proposed Sales

Value

$641.9K

Shares: 10.0K
Filed: Mar 5, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 10, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ARWR	-14.4%	-0.4%	+16.1%	-9.1%	+11.6%
SPY	-0.3%	+1.6%	+8.3%	+0.3%	+9.9%
vs SPY	-14.1%	-2.0%	+7.8%	-9.4%	+1.8%

Key facts CIK 879407 CUSIP 04280A100 13F (30d) 32 filings 27 filers Visit website Investor relations

ARWR

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance